Statins and risk of cancer: a systematic review and metaanalysis.

Int J Cancer 2007 Feb;120(4):833-43

Faculty of Medicine and Dentistry, University of Bristol, Bristol, United Kingdom.

We conducted a systematic review of the association between HMG-CoA reductase inhibitor (statin) use and cancer risk. We searched MEDLINE, EMBASE, Web of Science, ISI Proceedings and BIOSIS Previews bibliographic databases, electronic trials registers and reference lists for potentially eligible randomized trials and observational studies. Thirty-eight individual studies (26 randomized trials involving 103,573 participants and 12 observational studies with 826,854 participants) were included. Median follow-up was 3.6 and 6.2 years for trials and observational studies, respectively. In metaanalyses of randomized trials, there was no evidence that statin therapy was associated with incidence of all-cancers (26 trials; pooled risk ratio = 1.00; 95% CI 0.95-1.05; I(2) = 0%) or the following site-specific cancers: breast (7 trials; risk ratio = 1.01; 0.79-1.30; I(2) = 43%), prostate (4 trials; risk ratio = 1.00; 0.85-1.17; I(2) = 0%), colorectum (9 trials; risk ratio = 1.02; 0.89-1.16; I(2) = 0%), lung (9 trials; risk ratio = 0.96; 0.84-1.09; I(2) = 0%), genito-urinary (5 trials; risk ratio = 0.95; 0.83-1.09; I(2) = 0%), melanoma (4 trials; risk ratio = 0.86; 0.62-1.20; I(2) = 17%) or gastric (1 trial; risk ratio = 1.00; 0.35-2.85). There was no evidence of differential effects by length of follow-up, statin type (lipophilic vs. lipophobic) or potency. Trial results were generally consistent with observational studies. We conclude that statin use is not associated with short-term cancer risk, but longer-latency effects remain possible.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.22366DOI Listing
February 2007

Publication Analysis

Top Keywords

risk ratio
32
trials risk
24
observational studies
16
trials
12
ratio 100
12
randomized trials
12
risk
10
cancer risk
8
ratio
8
systematic review
8
trials observational
8
studies
5
effects length
4
length follow-up
4
826854 participants
4
participants included
4
colorectum trials
4
years trials
4
differential effects
4
follow-up years
4

References

(Supplied by CrossRef)
The statins as anticancer agents
Chan et al.
Clin Cancer Res 2003
The risk of cancer in users of statins
Graaf et al.
J Clin Oncol 2004
Statins and the risk of colorectal cancer
Poynter et al.
N Engl J Med 2005

National Institute for Health and Clinical Excellence et al.
2006

Similar Publications